Goin into my SA at a growing HC boutique. Been seeing a lot of stuff around here how this path is basically a banking career. How true is this? What are some prospects post biotech banking?
Also, how hard would it be get into the s tier HC (CVP, EVR, GS, Dyal) banking after or during my analyst years?
| +139 | Restructuring: Anti-climactic Experience | 36 | 8h |
| +110 | IB Net Worth / Savings Check | 51 | 7h |
| +100 | Woman who emptied Knicks trashcan on street then stole it was DEI exec, worked at JPMorgan Chase | 25 | 5h |
| +82 | Stop sleeping on UBS - it’s pretty good | 29 | 41m |
| +70 | Hot take: I’d rather be at Desjardins than UBS for investment banking in 2026 | 11 | 25m |
| +56 | 2026 VAULT PRESTIGE RANKINGS | 30 | 1h |
| +39 | AI + Financial Modelling | 12 | 1d |
| +32 | Hardest interview experiences? | 20 | 1h |
| +28 | Summer before college | 17 | 19h |
| +26 | Current State of UBS in North America | 8 | 2d |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
Based on the most helpful WSO content, here's what you need to know:
Prospects Post-Biotech Banking:
Biotech and healthcare (HC) investment banking can open up a variety of exit opportunities. Analysts in this space often transition to roles in venture capital (VC), private equity (PE), hedge funds (HF), or even operational roles at biotech startups. For example, some professionals move into VC firms that focus on life sciences or biopharma, where they can leverage their industry expertise. Others may join HFs or PE firms with a healthcare focus, or even take on strategic roles in biotech companies.
Transitioning to Top-Tier HC Banks (CVP, EVR, GS, Dyal):
Moving from a growing HC boutique to top-tier HC banks like Centerview Partners (CVP), Evercore (EVR), Goldman Sachs (GS), or Dyal Capital is challenging but not impossible. Success depends on several factors:
Challenges of the HC Boutique Path:
While HC boutiques provide excellent exposure to the healthcare and biotech sectors, they may not offer the same brand recognition or breadth of resources as top-tier banks. This can make transitioning to elite firms more competitive. However, if your boutique is growing and has a strong reputation in the HC space, it can still serve as a solid launching pad for your career.
In summary, while the HC boutique path may not have the same prestige as starting at a top-tier bank, it can still lead to excellent career prospects in biotech banking and beyond. With the right deal experience, networking, and skill development, transitioning to elite HC banks or exploring buy-side opportunities is achievable.
Sources: Medical School --> IBanking, Biotech finance: from IB to VC / HF to funded startup, Biotech IB - Which banks are best?, Healthcare Overview... Part 1?
Not sure about HC & Biotech specifically, but its always possible to lateral your way up to S-Tier
Knew someone who went from no name IB --> Baird --> GS Associate in 3.5 years out of undergrad in Industrials
Curious to hear other peoples thoughts as well
Leerink?
Porro est molestiae quibusdam quisquam iusto consequatur. Et voluptatem aut architecto eaque molestiae repudiandae error. Distinctio autem porro itaque inventore optio alias voluptatem rem.
Dolor et quae doloribus autem laboriosam natus esse itaque. Aliquid ea qui neque sint rem sint. Et qui velit reiciendis quis.
Voluptas perspiciatis debitis nulla earum sit pariatur. Nulla molestiae quo blanditiis tenetur id nam enim. Velit nam praesentium atque explicabo est.
Libero rerum ad iure ea. Blanditiis laborum cum autem iusto asperiores corporis. Harum asperiores eveniet dolor qui voluptatum dolore. Exercitationem maxime nihil dolore est ut dolore.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...